The addition of pembrolizumab to standard platinum-pemetrexed chemotherapy results in significant improvement in overall survival among patients with advanced pleural mesothelioma, according to a study published online Nov. ...
Nov 15, 2023
0
0
For patients with HER2-positive gastroesophageal junction (GEJ) adenocarcinoma, pembrolizumab improves progression-free survival when combined with chemotherapy and trastuzumab, according to a study published online Oct. ...
Oct 25, 2023
0
1
For patients with chemorefractory metastatic colorectal cancer, the KRAS G12C inhibitor sotorasib in combination with the epidermal growth factor receptor inhibitor panitumumab results in longer progression-free survival ...
Oct 24, 2023
0
0
A novel liquid biopsy test may help determine which patients with non-small cell lung cancer that has spread beyond the lungs are most likely to benefit from targeted, high-dose radiation, rather than drug-based therapy, ...
Oct 2, 2023
0
19
According to the American Journal of Roentgenology (AJR), using a 6-mm threshold, rather than a 5-mm threshold, helps facilitate better risk stratification and treatment decisions in patients with nasopharyngeal carcinoma ...
Sep 29, 2023
0
1
Dabrafenib plus trametinib results in significantly more responses and longer progression-free survival than standard chemotherapy for pediatric patients with low-grade glioma with BRAF V600 mutations, according to a study ...
Sep 21, 2023
0
16
The oral, selective KRAS G12C inhibitor KRAS-G12C inhibitor adagrasib demonstrated durable clinical activity, with a median overall survival of 14.1 months and approximately one in three patients alive at two years, according ...
Sep 9, 2023
0
18
The immunotherapy agent atezolizumab induces sustained responses in about one-third of patients with advanced alveolar soft part sarcoma (ASPS), according to a study published in the Sept. 7 issue of the New England Journal ...
Sep 8, 2023
0
26
A new agent that subverts myeloma cells from within while also subjecting them to an immune system attack produced impressive responses in combination with dexamethasone in patients with multiple myeloma that had relapsed ...
Aug 30, 2023
0
60
An international phase 3 clinical trial, done in participation with Weill Cornell Medicine and NewYork-Presbyterian, has found that a new targeted treatment called zolbetuximab, given in combination with a standard chemotherapy, ...
Aug 23, 2023
0
44
